To ensure that biotechnologically produced drugs are not recognized as foreign by the immune system and eliminated prematurely from the body, biotechnology uses different methods for modifying them so that effective drug delivery is possible.
celares gmbh is specialized in modifying biopharmaceuticals with polyethylene glycols (PEG), through which active ingredients have a longer effect in the body and are more soluble. Whereas in this technology the ingredients are chemically coupled with PEG, Alrise Biosystems GmbH encapsulates biotechnological ingredients with a microparticle envelope. This envelope prevents the drugs from decomposing in the liver, but instead allows them to be released in a controlled manner into the body.
The above technologies not only reduce side effects; the drugs also need to be taken less frequently.
Drug delivery is not only interesting for newly developed substances: Biopharmaceuticals already on the market can gain new patent protection with the aid of a new form of administration.
Q1 Performance Stable despite Oil Price Slump and Corona Expenses. Strong Growth in Radiopharmaceutical Products
Despite heavy burdens from corona and the drop in oil prices, Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, TecDAX), a specialist for isotope applications in medicine, science a...more ...
US health authorities to provide USD 6 million in funding for MYELO radiation protection pill
Berlin-based MYELO Therapeutics, an affiliated company of Eckert & Ziegler Strahlen- und Medizintechnik AG, will receive USD 6 million from the National Institutes of Health (NIH) over the next three ...more ...
Eckert & Ziegler Enters TecDAX
The Berlin-based Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, S-DAX) a specialist in isotope-related applications in medicine, science and industry, will enter the TecDAX effec...more ...